A weekly trade journal catering to the Indian chemical industry
backBack

calendar 18 August, 2026 15:33:33 IST

Again acquires Genomatica, merging AI molecule design with biomanufacturing scale-up

Article image

Danish technology company Again has acquired US-based Genomatica (Geno), uniting Again’s biomanufacturing scale-up capabilities with Geno’s AI-driven discovery and design platform. Terms of the transaction were not disclosed.

The deal combines Geno’s computational capabilities in de novo molecule discovery and design — built on two decades of in silico pathway and strain design and predictive machine learning — with Again’s AI-driven bioprocess design suite, creating what the companies describe as the industry’s most complete artificial intelligence design engine for biomanufacturing.

By merging Geno’s simulation capabilities with Again’s scale-up modelling and engineering expertise, the combined platform aims to address not just simulation but the harder challenge of scaling biological processes to industrial production.

The companies said the acquisition would compress the timeline from de novo pathway design to industrial execution, enabling high-throughput deployment across diverse feedstock sources. They also pointed to the timing of the deal, coming as reshoring accelerates under policies such as the US Biosecure Act and the EU’s Biotech Act II, which are expected to mobilise tens of billions of dollars in investment to strengthen domestic bio-based supply chains.

Central to the acquisition is Geno’s data — including its AI and computational biotech platform, patent portfolio, and data spanning experimental results, structural and scale-up insights, and development outcomes — which will feed into Again’s computational engines to sharpen its models and shorten development timelines. The combined company will operate across the full value chain, from pathway discovery to industrial-scale manufacturing, giving Again three ways to generate value: licensing technology, co-developing mission-critical production pathways, and selling products from existing and upcoming assets.

Mr. Max Kufner, CEO of Again, said AI was transforming biology but that algorithms were only as valuable as their ability to translate into real-world, commercial-scale execution. He said integrating Geno’s pioneering AI and computational biotechnology capabilities with Again’s scale-up platform and novel feedstock technologies would help build what he described as the world’s leading biomanufacturing platform.

Again operates across Copenhagen, Munich and Houston, developing technologies for partners in the industrial, personal and home care, food and feed markets. Geno, founded in 1998, has commercialised biological processes for widely used chemicals and materials, building one of the industry’s deepest proprietary bioprocess datasets and patent portfolios. As part of the acquisition, Geno’s technology, intellectual property and commercial footprint will be fully integrated into the Again platform, with existing Geno partners continuing to be supported through the transition.

article image
calender image

calender image 9 November, 2026 20:19:59 IST

Will India’s butadiene paradox resolve through integrated C4 value chain development?

India is at an important turning point in the development of its butadiene value chain. For years, the country...
article image

calender image 9 November, 2026 19:59:03 IST

GAIL subsidiary commissions PTA plant at Mangalore

GAIL (India) Ltd. has commissioned a 1.25-mtpa purified terephthalic acid (PTA) plant at the Mangalore Special Economic Zone...

PRINT EDITION

View Past Issues

Search For

Exhibitions & Conferences

ChemExpo IndiaChemProTechChemLogistics India

Watch

KKBangEchemiGPCA ForumCPHI PMEC INDIA